Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Health Informatics System Ensures Better Diabetes Care
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Charles L.
Received at Customer Service Chat Message Thursday, March 16, 2023 at 12:19 PM PDT
(Unedited)

I'd shared my experience with my diabetes class, and hopefully your company will be getting calls to try your products.

My A-1C is now 5.6. Thanks to your Marvlix and my heart Doctor took me off of his pill.

Have a great day.

Charles L.

Letter II: From Michael H.
Received at customerservice @ ezorbonline.com Thursday, March 2, 2023 at 01:18 PM PST
(Unedited)

Thank you very much for your informative reply on dialysis. Now I know. I'm very thankful to your company for helping others.

Elixir products have helped me when I had lost hope for my condition. I was diagnosed via bone density scan August 2022 that I was suffering from osteoporosis and had 2 fractured vertebrae from the condition.

I'm age 78. Lot of pain and I couldn't take Fosamax due to esophagus erosion. I have, since October 2022 been on Calcium Aspartate Anhydrous maximum dose for about 4 months and now take 6 capsules per day.

I noticed my pain gradually subsiding by the 3-4 month mark. I'm back to working in the yard again. My chiropractor was a tremendous help in keeping my vertebrae aligned while they were healing.

You are welcome to publish my message in order to help others in the same condition. Thank you.

Michael H.

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

Janaka Karalliedde of Guy’s and St Thomas’ NHS Foundation Trust in London, UK, revealed the findings at the 16th ATTD conference in Berlin, Germany.

He described the system as “an opportunity for us to change the way we deliver care - looking at prioritization in a more sophisticated, data-driven way, where people who are at lower risk may be given opportunities for patient-initiated follow-up, remote monitoring, to enable capacity to see those at higher risk more promptly.”

The system categorized people according to the recent occurrence of six high-risk events: receipt of diabetes-related emergency healthcare; a glycated hemoglobin measurement that was greater than 86 mmol/mol (gt 10%), less than 48 mmol/mol (lt 6.5%), or had changed by more than 20 mmol/mol (gt 4%) in either direction; a fall in estimated glomerular filtration rate greater than 15 mL/min per 1.73 m2; or receipt of treatment for advanced diabetic eye disease.

One or more of these events had occurred in 16.3% of 4013 adults with diabetes (48% women, 20% with type 1 diabetes) since their most recent clinic visit at a large London hospital. These 656 people were more frequently non-Caucasian and from a more deprived socioeconomic background than those without recent high-risk events, and about 7% were not due to be seen for at least 3 months or had no booked appointment.

Conversely, 174 people with “encouraging” glycemic and renal data were given a green flag, allowing physicians to reschedule forthcoming clinic visits by moving these people to later dates, ensuring that red-flagged people were offered an appointment date within the next 3 months.

For testing purposes, nine clinicians studied the data of 450 study participants and red-flagged those with concerning health indicators; the automatic system identified 83% of these people, as well as 81% of those green-flagged by the clinicians.

Karalliedde described this as “relatively good,” taking into account that clinicians “have varied degrees of risk awareness and risk threshold.”

The investigators then set up a high-risk clinic, in which they have so far seen nearly 100 people with diabetes. They believe that they have prevented harm – “predominantly hypoglycemia emergencies” - in about 40% of these people by bringing forward their clinic visits.

Moreover, the system may help to prevent health inequality, said Karalliedde, noting that 45% of the high-risk group was from an ethnic minority, compared with 30% of the overall cohort.

“Tools such as ours, we feel, can identify new, emerging risk, but most importantly deliver equitable, fairer healthcare, improve healthcare efficiency, and reduce the burden of complications in people with diabetes,” concluded the presenter.

Original paper was presented at ATTD 2023; Berlin, Germany: 22–25 February.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index